Providing Your
Practice With Reliable
HA Injections,
And A Complete
Suite Of Support
Services.



Simplicity & Convenience, Experience The Difference.

When it comes to hyaluronic acid (HA) injections, your success is our success. That's why we're always looking for ways to ensure every engagement and interaction with us is simple and stress-free. We're committed to your practice by providing not only GenVisc®850, but HARMOKNEE®, our comprehensive suite of practice support services designed to make accessing HA for your patients easy while saving you time. HA injections may be a small part of your practice, but convenient access is especially important since it allows you and your patients to get back to the things that matter.





GenVisc850 is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, GenVisc850 is approved in 64 countries with over 45 million syringes distributed worldwide.¹

Proven⁺

- GenVisc850 has the largest and longest duration double blind clinical study of hyaluronic acids for knee osteoarthritis.²
- GenVisc850 has been published in over 30 clinical studies.³

Effective

- Demonstrated improvement in pain relief may last up to 30 weeks post first injection cycle⁴
- Demonstrated improvement of total WOMAC index at 30 weeks:
 Pain, stiffness and functional capacity⁵
- Approved for 5 injections but some patients may benefit from as few as 3 injections⁶

Safe⁷

- · Safe as saline placebo
- Free of avian proteins
- Demonstrated safe for repeat injection cycles

HA Support For Your Practice. HA Support For Your Patients. That's Harmoknee®.

With HARMOKNEE practice support services, we aim to eliminate the uncertainty and busy work that gets in the way of your daily operations. From ordering HA and submitting prior authorizations, to offering a patient payment program, HARMOKNEE means your practice can deliver the best patient experience possible. To learn more, visit **harmonknee.support**



HARMOKNEE® PRACTICE SUPPORT SERVICES



Reimbursement Navigator

An online portal that can save time and money in the reimbursement and prescribing process.



Customer Service Specialists

Our team will partner with yours to tailor solutions to your practice and provide assistance when you need it.



Ordering Portal

Our intuitive online portal puts next-day HA delivery at your fingertips.



Direct Purchase Program

Patients can now purchase HA directly from our exclusive pharmacy network, no insurance or prior authorization needed. FSA and HSA eligible.



Flexible Distribution and Wholesale Options

An exclusive pharmacy network of experienced specialty distributors.



Medical Information Inquiries

Requests for medical information replied to within 24 hours.



Practice and Patient Support

We provide materials that address common questions about OA knee pain and HA injections.



To set up an account: 1-267-753-6700 or email: customerservice@orthogenrx.com

Ordering Portal: orthogenrx.pharmarxorder.com

Reimbursement Navigator:

orthogenrx.aspnprograms.com

Direct Purchase Program Customer Support:

866-556-2259

Product Code: 50653-006-01



Visit GenVisc850.com or scan for full safety and prescribing information.

References

- FDA summary of safety and effectiveness data (SSED). GenVisc® 850. www.accessdata.fda. gov/cdrh_docs/pdf14/p140005b.pdf. Accessed April 17, 2018
- 2., 5. Navarro-Sarabia F, Coronel P, Collantes E, Navarro FJ, de la Serna AR, Naranjo A, Gimeno M, Herrero-Beaumont G; AMELIA study group. A 40-month multicentre, randomised placebo- controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project. Ann Rheum Dis. 2011;70: 1957-62.
- 3.,4.,6.,7. GenVisc 850 Package Insert.
- Blanco FJ, Fernández-Sueiro JL, Pinto-Tasende JA, Fernández-López JC, Ramallal M, Freire A et al. Intra-articular hyaluronan treatment of patients with knee osteoarthritis waiting for replacement surgery. The Open Arthritis Journal 2008; 1: 1-7
- † The Adant® formulation is approved in 63 countries outside the US. Adant is manufactured by TEDEC-MEJJI FARMA and is authorized to be marketed and distributed under the trademark GenVisc850.



5 injection hyaluronic acid regimen



multi-regimen hyaluronic acids

AN AVANOS COMPANY

Distributed by:
OrthogenRx®,Inc
Doylestown Commerce Center
2005 S. Easton Road, Suite 207
Doylestown, PA 18901
267-753-6700

Manufactured by: Meiji Pharma Spain, S.A. Avda. De Madrid 94. 28802 Alcalá de Henares (Madrid), Spain

Adant is a registered trademark of TEDEC-MEIJI FARMA. GenVisc 850 is a registered trademark of OrthogenRx, Inc.